巨子生物最新声明！可复美检测数据曝光，华熙生物“宣战”遭硬怼

Core Viewpoint - The domestic medical beauty industry is experiencing a "component storm," highlighted by a fierce dispute between two major players, Giant Bio and Huaxi Bio, over the actual content of "recombinant collagen" in their products, escalating from product composition doubts to a public "business war" [2][3] Group 1: Industry Dispute - The controversy was ignited by a report from Dr. Hao Yu, which claimed that the recombinant collagen content in Giant Bio's product was only 0.0177%, significantly below the stated level of over 0.1% [3] - Giant Bio responded by asserting that the accusations were "seriously inaccurate" and provided self-test results confirming compliance with standards [3][5] - Huaxi Bio publicly supported Dr. Hao and accused Giant Bio of using online tactics to manipulate public perception, escalating the conflict [5] Group 2: Market Impact - Following the dispute, regulatory authorities in Shaanxi Province initiated an investigation, and the stock market reacted with Giant Bio's shares dropping approximately 13% while Huaxi Bio's shares rose about 9.8% [6] - The market's focus on recombinant collagen has surged, with a report indicating a compound annual growth rate of 63% from 2017 to 2022, and an expected growth rate of 42.4% from 2022 to 2027, reaching 108.3 billion [9] Group 3: Financial Performance - Despite the controversies, Giant Bio's performance remains strong, with a projected revenue of 55.39 billion in 2024, a 57% year-on-year increase, and a net profit of 20.62 billion, up 42% [11] - The brand Kefu Mei contributed 45.4 billion to revenue, accounting for 82% of total sales, but the company faces risks due to its heavy reliance on this single brand [11][14] Group 4: Industry Standards - The dispute highlights the lack of unified testing standards for recombinant collagen, leading to significant discrepancies in results from different testing institutions [10] - The National Medical Products Administration has initiated the establishment of industry standards for recombinant collagen testing methods, indicating a move towards regulatory improvement [10]